| Literature DB >> 19403315 |
Hassane Izzedine1, Rastilav Bahleda, David Khayat, Christophe Massard, Nicolas Magné, Jean Philippe Spano, Jean Charles Soria.
Abstract
It is now clearly established that anti-vascular endothelial growth factor (VEGF) drug class induces hypertension and proteinuria sometimes related to thrombotic microangiopathy and/or various glomerulopathies, according to capillary and glomerular VEGF and VEGF-receptor expressions. As reported in the literature, anti-epidermal growth factor receptor (EGFR) therapies seem to be less nephrotoxic. Indeed, many reports of anti-EGFR nephrotoxicity are tubular dependent such as acute tubular necrosis, electrolyte disorders (hypophosphatemia, hypomagnesemia, etc.) or both. This is explained by elective tubular expression of renal EGF/EGFR. In this paper, we focus on electrolyte disorders related to anti-EGFR treatment and discuss the tubular involvement of these drugs based on their renal expression. Crown Copyright 2009. Published by Elsevier Ireland Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19403315 DOI: 10.1016/j.critrevonc.2009.03.012
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN: 1040-8428 Impact factor: 6.312